Molecular Partners AG (MOLN)
| Market Cap | 178.74M +31.1% |
| Revenue (ttm) | n/a |
| Net Income | -63.35M |
| EPS | -1.68 |
| Shares Out | 38.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,422 |
| Open | 4.670 |
| Previous Close | 4.652 |
| Day's Range | 4.500 - 4.670 |
| 52-Week Range | 3.530 - 5.360 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 10.73 (+133.01%) |
| Earnings Date | Aug 25, 2026 |
About MOLN
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D... [Read more]
Analyst Summary
According to 5 analysts, the average rating for MOLN stock is "Strong Buy." The 12-month stock price target is $10.73, which is an increase of 133.01% from the latest price.
News
Molecular Partners AG Slides: Q2 2026
Molecular Partners AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 25, 2026.
Molecular Partners AG Earnings release: Q2 2026
Molecular Partners AG released its Q2 2026 earnings on August 25, 2026, summarizing the period's financial results.
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech compa...
Molecular Partners doses first patients in MP0317 combination study
Molecular Partners (MOLN) announced the dosing of first patients in an investigator-initiated Phase 2 proof-of-concept study of MP0317 in combination with chemoimmunotherapy in first line treatment fo...
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom...
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biote...
Molecular Partners, Orano Med doses first patient in MP0712 study
Molecular Partners (MOLN) and Orano Med announced that the first patients were dosed in the ongoing U.S. multicenter Phase 1/2a study of drug candidate MP0712.
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN),...
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
Molecular Partners (MOLN) announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of...
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Molecular Partners AG Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
DARPins offer a flexible, modular platform for radioligand therapy, with MP0712 showing promising early safety and tumor-targeting data in small cell lung cancer. MP0726 targets mesothelin with a unique approach, and additional pipeline assets are advancing, with key data and disclosures expected over the next 12–18 months.
Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-bu...
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Molecular Partners AG Earnings release: Q1 2026
Molecular Partners AG released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Molecular Partners AG Slides: Corporate presentation
Molecular Partners AG has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-...
Molecular Partners publishes MP0317 clinical data in Nature Cancer
Molecular Partners (MOLN) announced the publication of Phase 1 clinical data in Nature Cancer demonstrating the potential of the tumor-localized CD40 agonist, MP0317, to modulate the tumor microenviro...
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners announces presentation of preclinical data at AACR
Molecular Partners (MOLN) announced the presentation of new preclinical data across three posters at the American Association for Cancer Research, AACR, Annual Meeting 2026. The first poster outlines ...
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom...
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotec...
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners to Hold Three Poster Presentations at AACR 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schlieren, Switzerland and Concord, Mass., March 12, 2026 – Ad hoc announcement pursuant to Art. 53 LR Molec...